Cargando…
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
BACKGROUND: Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. We evaluated the efficacy of oral 5-fluorouracil-based S-1 as second- or third-line therapy compared with standa...
Autores principales: | Nokihara, H, Lu, S, Mok, T S K, Nakagawa, K, Yamamoto, N, Shi, Y K, Zhang, L, Soo, R A, Yang, J C, Sugawara, S, Nishio, M, Takahashi, T, Goto, K, Chang, J, Maemondo, M, Ichinose, Y, Cheng, Y, Lim, W T, Morita, S, Tamura, T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834128/ https://www.ncbi.nlm.nih.gov/pubmed/29045553 http://dx.doi.org/10.1093/annonc/mdx419 |
Ejemplares similares
-
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC
por: Sugawara, Shunichi, et al.
Publicado: (2019) -
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial
por: Yang, James Chih-Hsin, et al.
Publicado: (2021) -
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic
gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012) -
A randomised phase II trial of preoperative chemotherapy of cisplatin–docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204)
por: Kunitoh, H, et al.
Publicado: (2008) -
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
por: Sekine, I, et al.
Publicado: (2008)